Pono Pharma

Pono Pharma is a private biotechnology company based in San Diego, California, focused on the discovery and development of next-generation small molecule therapeutics for oncology. The company specializes in targeting the RAS signaling pathway, which is a primary driver in many difficult-to-treat cancers. Pono Pharma's research efforts are centered on developing potent and selective inhibitors for specific KRAS mutations, including G12D and G12V, as well as targeting the SOS1 protein to modulate RAS activity. By leveraging deep expertise in medicinal chemistry and cancer biology, the company aims to create precision medicines that overcome the limitations and resistance mechanisms of existing therapies. Pono Pharma is currently advancing its lead programs through the pre-clinical stage of development.